Suppr超能文献

两种与轻度和重度常染色体显性遗传性新生血管性炎症性玻璃体视网膜病变表型相关的新型 CAPN5 变异。

Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes.

机构信息

a NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust , Oxford , United Kingdom.

b Oxford Eye Hospital, University of Oxford NHS Trust, John Radcliffe Hospital , Oxford , United Kingdom.

出版信息

Ocul Immunol Inflamm. 2019;27(5):693-698. doi: 10.1080/09273948.2017.1370651. Epub 2017 Oct 17.

Abstract

: We report two new CAPN5 mutations associated with a phenotype of Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. : We performed next generation sequencing in two patients with ADNIV phenotype; the variants identified were explored further. : Patient 1 was heterozygous for CAPN5 c.799G>A, p.(Gly267Ser). Patient 2 was heterozygous for CAPN5 c.1126G>A, p.(Gly376Ser). Both amino acids are highly conserved across species. Patient 1 had a severe phenotype and his mutation lies within the protein's catalytic domain. Patient 2 had a mild phenotype and her mutation is the first ADNIV-causing mutation to be described in the regulatory domain of Calpain-5. : Our findings potentially add two new ADNIV-causing CAPN5 mutations to the three previously described. We recommend CAPN5 genetic testing in all patients with a possible ADNIV phenotype, to develop our understanding of Calpain-5; a protein which could potentially provide therapeutically accessible targets for the treatment of many leading causes of blindness.

摘要

我们报告了两个与常染色体显性新生血管性炎症性玻璃体视网膜病变表型相关的 CAPN5 新突变。我们对两个具有 ADNIV 表型的患者进行了下一代测序;进一步探讨了鉴定出的变体。患者 1 为 CAPN5 c.799G>A,p.(Gly267Ser)杂合子。患者 2 为 CAPN5 c.1126G>A,p.(Gly376Ser)杂合子。这两个氨基酸在不同物种中高度保守。患者 1 表现出严重的表型,其突变位于蛋白的催化结构域内。患者 2 的表型较轻,她的突变是第一个在 Calpain-5 调节结构域中描述的导致 ADNIV 的突变。我们的发现可能为先前描述的三个突变增加了两个新的导致 ADNIV 的 CAPN5 突变。我们建议对所有可能具有 ADNIV 表型的患者进行 CAPN5 基因检测,以加深对 Calpain-5 的理解;这种蛋白可能为治疗许多主要致盲原因提供可治疗的靶向治疗。

相似文献

1
Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes.
Ocul Immunol Inflamm. 2019;27(5):693-698. doi: 10.1080/09273948.2017.1370651. Epub 2017 Oct 17.
2
Structural modeling of a novel CAPN5 mutation that causes uveitis and neovascular retinal detachment.
PLoS One. 2015 Apr 9;10(4):e0122352. doi: 10.1371/journal.pone.0122352. eCollection 2015.
3
Early Onset Neovascular Inflammatory Vitreoretinopathy Due to a Mutation: Report of a Case.
Ocul Immunol Inflamm. 2019;27(5):706-708. doi: 10.1080/09273948.2019.1582783. Epub 2019 Apr 15.
4
Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina.
Hum Mol Genet. 2014 May 15;23(10):2665-77. doi: 10.1093/hmg/ddt661. Epub 2013 Dec 30.
6
Lymphocyte infiltration in CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy.
Clin Ophthalmol. 2013;7:1339-45. doi: 10.2147/OPTH.S46450. Epub 2013 Jul 3.
7
Early-onset Neovascular Inflammatory Vitreoretinopathy Due to Two de Novo CAPN5 Mutations in Chinese Patients: A Case Series.
Ocul Immunol Inflamm. 2023 Nov;31(9):1777-1784. doi: 10.1080/09273948.2022.2110901. Epub 2022 Nov 11.
10
Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy.
Clin Ophthalmol. 2012;6:2037-44. doi: 10.2147/OPTH.S40086. Epub 2012 Dec 6.

引用本文的文献

1
The Identification of Proteolytic Substrates of Calpain-5 with N-Terminomics.
Int J Mol Sci. 2025 Jul 4;26(13):6459. doi: 10.3390/ijms26136459.
2
Bilateral macular hole in a patient with CAPN5-related neovascular inflammatory vitreoretinopathy.
Doc Ophthalmol. 2023 Dec;147(3):211-216. doi: 10.1007/s10633-023-09946-7. Epub 2023 Sep 5.
3
Impaired activity and membrane association of most calpain-5 mutants causal for neovascular inflammatory vitreoretinopathy.
Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166747. doi: 10.1016/j.bbadis.2023.166747. Epub 2023 May 18.
4
Phenotypic variance in Calpain-5 retinal degeneration.
Am J Ophthalmol Case Rep. 2020 Feb 24;18:100627. doi: 10.1016/j.ajoc.2020.100627. eCollection 2020 Jun.
5
Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations.
JAMA Ophthalmol. 2020 May 1;138(5):544-551. doi: 10.1001/jamaophthalmol.2020.0666.
7
CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials.
Hum Mutat. 2019 Dec;40(12):2377-2392. doi: 10.1002/humu.23894. Epub 2019 Aug 26.
8
Capn5 Expression in the Healthy and Regenerating Zebrafish Retina.
Invest Ophthalmol Vis Sci. 2018 Jul 2;59(8):3643-3654. doi: 10.1167/iovs.18-24278.
9
Olfactory Dysfunction in Patients With CNGB1-Associated Retinitis Pigmentosa.
JAMA Ophthalmol. 2018 Jul 1;136(7):761-769. doi: 10.1001/jamaophthalmol.2018.1621.
10
A novel de novo mutation in a patient with inflammatory vitreoretinopathy, hearing loss, and developmental delay.
Cold Spring Harb Mol Case Stud. 2018 Jun 1;4(3). doi: 10.1101/mcs.a002519. Print 2018 Jun.

本文引用的文献

1
Calpain-5 Expression in the Retina Localizes to Photoreceptor Synapses.
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2509-21. doi: 10.1167/iovs.15-18680.
3
Structural modeling of a novel CAPN5 mutation that causes uveitis and neovascular retinal detachment.
PLoS One. 2015 Apr 9;10(4):e0122352. doi: 10.1371/journal.pone.0122352. eCollection 2015.
6
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.
Lancet. 2014 Mar 29;383(9923):1129-37. doi: 10.1016/S0140-6736(13)62117-0. Epub 2014 Jan 16.
7
Functional validation of a human CAPN5 exome variant by lentiviral transduction into mouse retina.
Hum Mol Genet. 2014 May 15;23(10):2665-77. doi: 10.1093/hmg/ddt661. Epub 2013 Dec 30.
10
Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration.
PLoS Genet. 2012;8(10):e1003001. doi: 10.1371/journal.pgen.1003001. Epub 2012 Oct 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验